Letrozole
Femara, Letrozole (letrozole) is a small molecule pharmaceutical. Letrozole was first approved as Femara on 1997-07-25. It is used to treat breast neoplasms in the USA. The pharmaceutical is active against aromatase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Femara, Letrozole (discontinued: Letrozole)
CombinationsKisqali femara co-pack
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| femara | New Drug Application | 2025-08-21 |
| kisqali femara co-pack | New Drug Application | 2025-07-28 |
| letrozole | ANDA | 2025-06-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LETROZOLE / RIBOCICLIB SUCCINATE, KISQALI FEMARA CO-PACK (COPACKAGED), NOVARTIS | |||
| 2024-12-10 | NPP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Letrozole / Ribociclib Succinate, Kisqali Femara Co-Pack (Copackaged), Novartis | |||
| 10799506 | 2036-04-14 | DP | |
| 9193732 | 2031-11-09 | DS, DP | |
| 9868739 | 2031-11-09 | U-2505, U-3264 | |
| 8415355 | 2031-03-13 | DS, DP | |
| 8685980 | 2030-05-25 | DS, DP | |
| 8962630 | 2029-12-09 | U-2505, U-3264 | |
| 9416136 | 2029-08-20 | U-2505, U-3264 | |
| 8324225 | 2028-06-17 | DS, DP | |
HCPCS
No data
Clinical
Clinical Trials
826 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 82 | 277 | 127 | 32 | 74 | 555 |
| Infertility | D007246 | EFO_0000545 | — | 5 | 8 | 16 | 14 | 22 | 62 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 6 | 3 | 16 | 6 | 22 | 51 |
| Neoplasms | D009369 | — | C80 | 13 | 18 | 4 | 2 | 8 | 39 |
| Syndrome | D013577 | — | — | 3 | 4 | 7 | 5 | 14 | 31 |
| Triple negative breast neoplasms | D064726 | — | — | 8 | 17 | 3 | 1 | 1 | 29 |
| Carcinoma | D002277 | — | C80.0 | 7 | 12 | 5 | 1 | 3 | 27 |
| Male breast neoplasms | D018567 | — | — | 4 | 8 | 9 | 1 | 5 | 26 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 7 | 5 | 2 | 2 | 15 |
| Spontaneous abortion | D000022 | EFO_1001255 | O00.1 | — | 4 | 3 | 3 | 4 | 12 |
Show 38 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 4 | 22 | 4 | — | 1 | 25 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 15 | 5 | — | — | 21 |
| Recurrence | D012008 | — | — | 2 | 13 | 3 | — | 3 | 20 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 2 | 9 | 4 | — | — | 13 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | 6 | 2 | — | — | 8 |
| Intraductal carcinoma noninfiltrating | D002285 | — | D05.1 | 2 | 4 | 1 | — | 1 | 7 |
| Lobular carcinoma | D018275 | EFO_0000570 | — | 1 | 1 | 4 | — | — | 6 |
| Carcinoma in situ | D002278 | — | D09.9 | 3 | 3 | 1 | — | — | 6 |
| Breast diseases | D001941 | — | N60-N65 | — | 4 | 1 | — | 1 | 5 |
| Neoadjuvant therapy | D020360 | — | — | — | 2 | 3 | — | — | 5 |
Show 25 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometriosis | D004715 | EFO_0001065 | N80 | — | 2 | — | — | 3 | 5 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 1 | — | — | — | 3 |
| Leiomyosarcoma | D007890 | — | — | — | 3 | — | — | — | 3 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | 2 | 3 |
| Sarcoma | D012509 | — | — | 1 | 2 | — | — | — | 3 |
| Disease progression | D018450 | — | — | — | 1 | — | — | 1 | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 2 | — | — | — | 2 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | 1 | — | — | 1 | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 1 | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 2 |
Show 31 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | — | — | — | — | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | — | — | — | — | 2 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | — | 2 |
| Overweight | D050177 | — | E66.3 | 1 | — | — | — | 1 | 2 |
| Premenopause | D017697 | — | — | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Liposarcoma | D008080 | — | — | 1 | — | — | — | — | 1 |
| Adenocarcinoma of lung | D000077192 | — | — | 1 | — | — | — | — | 1 |
| Malignant mesothelioma | D000086002 | — | — | 1 | — | — | — | — | 1 |
| Mesothelioma | D008654 | — | C45 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cicatrix | D002921 | — | L90.5 | — | — | — | — | 2 | 2 |
| Reproductive behavior | D043762 | — | — | — | — | — | — | 1 | 1 |
| Mouth neoplasms | D009062 | EFO_0003868 | C06.9 | — | — | — | — | 1 | 1 |
| Thrombosis | D013927 | — | — | — | — | — | — | 1 | 1 |
| Vaginitis | D014627 | EFO_0005757 | N76 | — | — | — | — | 1 | 1 |
| Atrophic vaginitis | D059268 | EFO_1001271 | — | — | — | — | — | 1 | 1 |
| Pregnancy rate | D018873 | — | — | — | — | — | — | 1 | 1 |
| Radiotherapy | D011878 | — | — | — | — | — | — | 1 | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 1 | 1 |
| Periodontal diseases | D010510 | — | K05.6 | — | — | — | — | 1 | 1 |
Show 21 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Letrozole |
| INN | letrozole |
| Description | Letrozole is a member of triazoles and a nitrile. It has a role as an antineoplastic agent and an EC 1.14.14.14 (aromatase) inhibitor. |
| Classification | Small molecule |
| Drug class | aromatase inhibitors (imidazole/triazole derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 112809-51-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1444 |
| ChEBI ID | 6413 |
| PubChem CID | 3902 |
| DrugBank | DB01006 |
| UNII ID | 7LKK855W8I (ChemIDplus, GSRS) |
Target
Agency Approved
CYP19A1
CYP19A1
Organism
Homo sapiens
Gene name
CYP19A1
Gene synonyms
ARO1, CYAR, CYP19
NCBI Gene ID
Protein name
aromatase
Protein synonyms
CYPXIX, Cytochrome P-450AROM, Cytochrome P450 19A1, cytochrome P450, family 19, subfamily A, polypeptide 1, cytochrome P450, subfamily XIX (aromatization of androgens), Estrogen synthase, estrogen synthetase, flavoprotein-linked monooxygenase, microsomal monooxygenase
Uniprot ID
Mouse ortholog
Cyp19a1 (13075)
aromatase (P28649)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Letrozole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,913 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
39,598 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use